> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Priority Review for Hepatitus C Therapy
- URL: https://www.fdaweb.com/fda-priority-review-for-hepatitus-c-therapy/
- Published: 2017-02-02T12:00:00.000Z
- Updated: 2026-09-14T22:04:25.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5137894

FDA has accepted for priority review an AbbVie NDA for its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P) for treating all major genotypes of chronic hepatitis C virus (HCV). The submission is supported by data from eight registration studies in AbbVie's G/P clinical development program, which evaluated more than 2,300 patients in 27 countries across all major HCV genotypes and for special populations, the company says. AbbVie is also studying G/P in patients with specific treatment challenges, such as genotype 3, patients who were not cured with previous treatment and those with kidney disease, including patients on dialysis.